Shares of Clovis Oncology Inc (NASDAQ:CLVS) have received a consensus recommendation of “Buy” from the twenty-one brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $86.50.
Several research firms have recently issued reports on CLVS. BidaskClub lowered shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Friday, February 9th. Cann reissued a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, February 27th. ValuEngine raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Oppenheimer reissued a “hold” rating on shares of Clovis Oncology in a research report on Wednesday, December 20th. Finally, Barclays set a $85.00 price target on shares of Clovis Oncology and gave the company a “buy” rating in a research report on Tuesday, February 27th.
Clovis Oncology (NASDAQ:CLVS) opened at $62.00 on Wednesday. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.69 and a quick ratio of 7.35. The firm has a market cap of $3,152.73, a PE ratio of -8.28 and a beta of 1.10. Clovis Oncology has a 52 week low of $45.42 and a 52 week high of $99.45.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $59.16, for a total transaction of $177,480.00. Following the sale, the insider now owns 183,571 shares of the company’s stock, valued at approximately $10,860,060.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $61.47, for a total transaction of $276,615.00. Following the sale, the director now directly owns 12,118 shares in the company, valued at approximately $744,893.46. The disclosure for this sale can be found here. Insiders have sold a total of 22,500 shares of company stock worth $1,371,210 in the last ninety days. 12.50% of the stock is currently owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Cypress Capital Management LLC WY increased its holdings in shares of Clovis Oncology by 272.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc bought a new position in shares of Clovis Oncology in the 3rd quarter worth $239,000. First Republic Investment Management Inc. bought a new position in shares of Clovis Oncology in the 3rd quarter worth $251,000. BB&T Securities LLC bought a new position in shares of Clovis Oncology in the 3rd quarter worth $288,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Clovis Oncology in the 4th quarter worth $328,000.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/clovis-oncology-inc-clvs-receives-average-rating-of-buy-from-analysts.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.